CSIMarket
 
Amphastar Pharmaceuticals Inc   (AMPH)
Other Ticker:  
 
 
Price: $42.8500 $-0.20 -0.465%
Day's High: $43.395 Week Perf: -2.94 %
Day's Low: $ 42.16 30 Day Perf: -22.81 %
Volume (M): 323 52 Wk High: $ 67.66
Volume (M$): $ 13,836 52 Wk Avg: $50.47
Open: $43.05 52 Wk Low: $35.62



 Market Capitalization (Millions $) 2,311
 Shares Outstanding (Millions) 54
 Employees 2,146
 Revenues (TTM) (Millions $) 601
 Net Income (TTM) (Millions $) 135
 Cash Flow (TTM) (Millions $) 114
 Capital Exp. (TTM) (Millions $) 35

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc is a publicly traded American pharmaceutical company founded in 1996 by Drs. Jack and Rex Zhang. The company is headquartered in Rancho Cucamonga, California and has a market capitalization of over $1 billion. Amphastar specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products.

The company has more than 20 injectable products in its portfolio, which includes anesthesia, analgesics, anti-infectives, cardiovascular, and central nervous system agents. Amphastar's most significant revenue generating product is enoxaparin sodium injection, a generic version of Sanofi's anticoagulant Lovenox. This product accounts for more than 50% of the company's total revenue.

Additionally, Amphastar has branded products, such as Primatene Mist, an over-the-counter inhaler used for the treatment of asthma symptoms. The company also has a pipeline of innovative products, including products in clinical trials for diabetes, hypoglycemia, and severe allergies.

The company has three manufacturing facilities located in California, which are equipped with the latest manufacturing technology and conform to the highest regulatory standards of the FDA and the European Medicines Agency (EMA).

In addition to its manufacturing capabilities, Amphastar has a robust research and development team that is responsible for developing new products and improving existing products. The company invests heavily in research and development, spending around 20% of its revenue on these activities.

Amphastar has a global presence and has distribution partnerships in many countries, including the United States, Europe, and Asia. The company has a diverse customer base that includes hospitals, wholesalers, and distributors.

Amphastar is committed to corporate social responsibility and strives to reduce its impact on the environment. The company has implemented sustainability programs that focus on energy efficiency, water conservation, and waste management.

In summary, Amphastar Pharmaceuticals is a leading pharmaceutical company that specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products. With a wide range of products, an innovative pipeline, and a strong commitment to sustainability, Amphastar is poised for continued growth and success in the pharmaceutical industry.


   Company Address: 11570 6th Street Rancho Cucamonga 91730 CA
   Company Phone Number: 980-9484   Stock Exchange / Ticker: NASDAQ AMPH
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Amphastar Pharmaceuticals Inc

Unbelievable Milestone Unveiled: Amphastar Pharmaceuticals Inc.'s Extraordinary Triumph Dominates the Fiscal Third Quarter of 2023!

Amphastar Pharmaceuticals Inc, a major player in the pharmaceutical industry, has had an impressive fiscal third quarter of 2023, with significant growth in both revenue and earnings per share. The company's revenue soared by an impressive 50.302% to $180.56 million, while its earnings per share grew rapidly by 203.33% to $0.91 per share compared to the corresponding quarter a year ago.
This outstanding performance sets Amphastar Pharmaceuticals apart from its sector contemporaries, as the Major Pharmaceutical Preparations sector only saw a 2.06% improvement in revenue during the same period. In comparison to the previous quarter, Amphastar Pharmaceuticals Inc's revenue improved by 23.913% from $145.71 million, and its earnings per share soared by 85.71% from $0.49 per share.

Amphastar Pharmaceuticals Inc

AMPH Surges 120% YTD despite Recent Decline, Leaves Investors Curious About Future Growth

During the past 5 trading days, Amphastar Pharmaceuticals Inc. (AMPH) stock experienced a decline of -1.38%. However, the year-to-date performance of the stock stands at an impressive 120.6%. This decline has led the stock to be 2.4% short of its 52-week high. These recent developments have left many investors wondering about the state of the company and its future prospects.
Amphastar Pharmaceuticals Inc. is a major player in the pharmaceutical preparations industry. Their most recent fiscal period was quite bewildering, as they witnessed a significant increase in profit per share. The profit per share surged by 48.48% to $0.49 per share, accompanied by a substantial revenue increase of 18.017% to $145.71 million, compared to the prior year period.

Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals Inc Soars with Impressive Revenue Surge in Q1 2023

Amphastar Pharmaceuticals Inc, a company operating in the Healthcare sector, reported its financial results for the first quarter of 2023. The company achieved a return on asset (ROA) of 12.54%, which is higher than its average ROA of 4.84%. However, the ROA decreased compared to the period ending December 31, 2022, due to a decline in net income. Furthermore, 34 other companies in the Healthcare sector had a higher return on assets than Amphastar Pharmaceuticals Inc.
Despite this, the company's overall ranking for ROA improved in the first quarter of 2023, with its total ROA ranking advancing from 582 in the fourth quarter of 2022 to 298. The double-digit revenue rise of 16.328% to $140.02 million led to a modest income rise of 6.38% to $0.50 per share in the fiscal period ending March 31, 2023, year on year. However, the earnings per share (EPS) fell by -19.66% from $0.62 per share reported in the previous financial reporting period, while revenue increased by 3.702% from $135.02 million.






 

Amphastar Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com